Status:

COMPLETED

Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

Lead Sponsor:

Laboratorios Sophia S.A de C.V.

Conditions:

Primary Open Angle Glaucoma

Ocular Hypertension

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

Aim: To demonstrate the non-inferiority of the PRO-122 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus Krytantek Ofteno® ophthalmic solution like hypotensive therapy in sub...

Detailed Description

The American Academy of Ophthalmology Glaucoma Panel: The primary open angle glaucoma (POAG) is a progressive, chronic optic neuropathy in adults in which intraocular pressure (IOP) and other currentl...

Eligibility Criteria

Inclusion

  • 18 years of age or older
  • male or female.
  • obtained in the external consultation.
  • With diagnosis primary of open-angle glaucoma and / or hypertension classified as mild, moderate or severe glaucomatous damage, users of Krytantek Ofteno® at least two months prior to inclusion and under control of the target IOP.
  • informed consent.

Exclusion

  • General Criteria
  • Subjects with topical or systemic medication that interferes decisively in the results of the study. (Such as topical immunomodulators, lacrimal point tamponade, corticosteroids, ocular hypotensives other than those listed above, artificial tears with preservative).
  • Subjects (female) with an active sex life who are not using a contraceptive method.
  • Female Subjects in pregnancy or breastfeeding.
  • Female subjects with positive urine pregnancy test.
  • Positive drug addiction (verbal interrogation).
  • Subjects who have participated in any clinical research study in the last 40 days.
  • Legally or mentally disabled subjects to give informed consent for their participation in this study.
  • Subjects who can not comply with the appointments or with all the requirements of the protocol.
  • Ophthalmologic criteria
  • Subject with only one eye with vision.
  • Subjects with visual capacity 20/200 or worse.
  • Subjects with a narrow-angle history without treatment, with or without total or partial closure of the angle in either eye.
  • Subjects with corneal abnormalities that prevent applanation tonometry.
  • Subjects with ocular surgery or ocular trauma 6 months prior to inclusion.
  • Any ocular laser surgery 3 months prior.
  • Any uncontrolled or progressive retinal disease.
  • Inflammatory diseases of any kind.
  • Contact lens wearers.
  • Subjects with a history of hypersensitivity to any of the ingredients of the research product or its analogues.

Key Trial Info

Start Date :

April 1 2016

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 18 2017

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT03257813

Start Date

April 1 2016

End Date

June 18 2017

Last Update

December 9 2019

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK) | DecenTrialz